Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status
Compose a Response to This Article
Other responses
No responses have been published for this article.